ProCE Banner Activity

Treatment of Acute Lymphoblastic Leukemia Measurable Residual Disease Using Blinatumomab

Clinical Thought
Here are my thoughts on the use of blinatumomab to treat patients with B-cell precursor acute lymphoblastic leukemia with measurable residual disease.

Released: September 28, 2018

Expiration: September 27, 2019

No longer available for credit.

Share

Faculty

Aaron C. Logan

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Adaptive Biotechnologies

Amgen, Inc.

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Aaron C. Logan, MD, PhD, has disclosed that he has received consulting fees from Amgen.